In vivo, PADI4-overexpressing ECA-109 cell lysate or rPADI4 cocultured CIK cells were injected into tumor-bearing mice can decline the tumor volume by 18.6% or 35.1% compared with the control group, which demonstrates that PADI4 can act as a tumor marker to enhance the therapeutic effect of DC-CIK cells in vivo. Here, PADI4 is linked to neoplasm.